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Abstract 
The aim of vascular tissue engineering (VTE) is to fabricate tissues that are both 
mechanically and biologically competent similar to the native vessel they are intended to 
replace. To this end, the incorporation of sufficient extracellular matrix elastin and collagen 
is important.  The objective of this thesis work was to evaluate the effect of two 
biochemical factors, L-ascorbic acid (AA) and all-trans retinoic acid (atRA), on elastin 
synthesis when coronary artery smooth muscle cells were cultured on 3D polycaprolactone 
(PCL) scaffolds. First, porous PCL scaffolds were fabricated using a solvent casting and 
particulate leaching approach. The effect of different solvents (ethyl acetate, chloroform 
and tetrahydrofuran) and PCL concentration on the morphology and porosity of the 
resulting scaffolds were studied. The best scaffolds (based on SEM and micro-CT analyses) 
were fabricated from 30% w/w PCL in ethyl acetate. Second, smooth muscle cells were 
cultured on these scaffolds to evaluate elastin synthesis.  It was found that concurrent 
addition of AA and atRA in both 2-D and 3-D cultures suppressed elastin protein 
expression compared with atRA alone. To overcome this effect, sequential biochemical 
factors addition was tested. The results demonstrated that sequential but not concurrent 
addition of biochemical agents promoted tropoelastin synthesis. This study suggested the 
importance of biochemical factor addition strategy to engineer a viable vascular tissue.  
 
Keywords: vascular tissue engineering, vascular smooth muscle cells, elastin, all-trans 
retinoic acid, L-ascorbic acid, PCL scaffolds.  
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Chapter 1 - Introduction 
 
1.1 Overview 
Despite significant progress made in intervention outcomes, cardiovascular disease (CVD) 
represents the leading cause of death worldwide. Diseases impacting the small diameter 
vasculature, such as the vessels servicing the coronary circulation, are becoming the 
leading cause of mortality for all of CVD [1]. Alarmingly, these trends are predicted to 
increase in the future, likely attributed to an aging population prone to making poor health 
decisions. Prophylactic measures to reduce the incidence of CVD have not been effective 
due to compliance issues.[2] For replacement of the diseased coronary arteries, autologous 
vessels such as the great saphenous vein or internal thoracic artery are the most viable 
options yet the likely presence of co-morbidities or removal from previous harvests 
indicate that other options are required. While it is possible to utilize allografts or 
xenografts, there are significant immune-mediated issues that arise that decrease the 
patency of these grafts. As such, there is need for the development of a therapeutically 
viable and highly patent small-diameter graft replacement. This can be accomplished 
through vascular tissue engineering (VTE) that aims to mimic a native vessel through 
synthetic fabrication methods. However, the success of such designs relies on matching the 
mechanical properties to that of the native vessels.[3] As collagen and elastin are the two 
main proteins that endow the native vessels with their mechanical properties, it is important 
to understand their expression in order for enhancement to occur in vitro. 
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While collagen can be increased in vitro through L-Ascorbic Acid (AA) addition, a main 
challenge of VTE is an inability to understand and promote elastogenesis. Elastin provides 
resiliency to the arteries and allows for the accommodation of cyclic loading during the 
cardiac cycle. It is thought that elastogenic factors, that aid in stimulating the process, 
represent viable avenues to explore. One such factor is all-trans retinoic acid (atRA) that is 
a derivative of vitamin A and essential during embryonic development. atRA has been 
shown to promote the expression of elastin in 2-D cultures. Additionally, atRA is suggested 
to have significant phenotypic control over vascular smooth muscle cells (vSMCs) 
whereby a contractile state is produced that is non-proliferative. Thus, atRA appears to be 
an ideal candidate for investigation as it can increase elastin while concurrently mitigating 
the risk of restenosis usually seen with surgical interventions.[4] That said, few studies have 
investigated the combination of AA and atRA on 3-D scaffolds and those that did utilize 
long end-points and failed to assess elastogenesis acutely compared to either factor alone.  
 
1.2 Thesis Outline 
The thesis contains five chapters that are based on investigations pertaining to the 
interaction of hcSMCs with 2-D and 3-D substrates and the fabrication process of 3-D 
scaffolds. Chapter 2 introduces the relevant literature of the vasculature anatomy, vascular 
disease progression, therapeutic options to treat the pathologies, followed by the need for 
vascular tissue engineering and options to augment elastogenesis. The motivation and 
objectives of this study are discussed at the end of the chapter. Chapter 3 introduces the 
materials and methods and outlines the techniques utilized. Chapter 4 discusses the major 
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findings and results from the work. Chapter 5 comments on the future directions of the 
work and potential implications of the findings. 
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Chapter 2 – Literature Review 
 
2.1 Vasculature Organization and Function 
2.1.1 Circulation Anatomy 
Blood vessels are hollow tubes that act as conduits for the cardiac output of the heart, 
allowing for systemic tissue perfusion with an oxygenated blood flow while facilitating the 
return of deoxygenated blood to the heart. The contraction of the left ventricle of the heart 
allows for the distribution of oxygenated blood systemically via the aorta, the initial 
segment of the arterial circulation. Distal to the aorta, numerous branches and bifurcations 
occur. Each newly created continuous segment is associated with an alternative lumenal 
diameter and deviation in the underlying structural detail of the vessel wall which imparts 
specific functionality.[5] The aorta transitions to smaller elastic then more muscular arteries 
which give rise to numerous arterioles and ultimately the capillaries.[5] The aorta acts as a 
Windkessel vessel, attempting to limit pulsatile blood flow in the periphery by dampening 
pulse pressure as it possesses relatively higher compliance than other derivatives in the 
arterial system.[6] The smaller arteries and the arterioles are more resistive in nature and 
thus have a larger impact on the maintenance of mean arterial pressure and control of distal 
flow. As the transition to arterioles occurs, there is a slight increase in the mean surface 
area of the vessels that reaches a maximum at the capillaries, which have the slowest flow 
velocity. Capillaries have the ideal hemodynamic characteristics for gas exchange and 
filtration or absorption due to their small wall thickness.[7] The capillaries converge after 
gas-exchange occurs at their proximal ends and become venules more distally, the first 
structure of the venous circulation. Most venules merge into smaller and then larger veins 
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that drain into the inferior or superior vena cava and back into the right atrium of the heart. 
Abnormalities in any section of this closed system will compromise downstream tissue 
perfusion and thus organ function. 
 
2.1.2 Arterial Circulation: Structural and Histological Detail 
The arterial wall is a tri-layered laminar structure consisting of the tunica intima, the tunica 
media, and the tunica adventitia.[5] Along the arterial tree, the composition of the arteries 
varies and similar, yet variant, stress-strain curves are observed.[8] Numerous studies have 
shown that the stress-strain curves will range from elastic to viscoelastic more distally with 
a continuum between these points.[5, 8, 9] The proceeding text describes the general features 
of an elastic or a more proximal muscular artery to which Figure 2.1 provides an overview 
of the arterial wall layers and underlying histological detail in cross-section. 
 
The tunica intima is the innermost layer of the vessel wall that is exposed to the blood flow. 
It is composed of a mono-layer lining of endothelial cells (ECs) upon a basement 
membrane with a sub-endothelial matrix consisting of loose connective tissue, myointimal 
cells, fibroblasts, and extra-cellular constituents. Deep to the tunica intima lies the tunica 
media, a muscular layer consisting of circumferentially orientated smooth muscle cells 
(SMCs) and interspersed extra-cellular matrix fibers in a lamellar organization. The 
junction between the tunica media and overlying tunica intima is delineated by an internal 
elastic lamina, which assists in volume accommodation during the cardiac cycle and may 
have a role in SMC migration from the medial layer.[10] An external elastic lamina lies 
deeper and marks the junction between the overlying tunica media and the tunica 
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adventitia. The latter layer is more connective tissue in nature with fibroblasts in addition 
to collagenous fibers orientated longitudinally. 
 
Figure 2.1: A. Longitudinal section of an artery indicating the exposed vessel wall layers. 
B. Histological cross-section indicating extensive lamellar elastin distribution within the 
medial layer.[11]  Used with permission from the Publisher.  
 
2.1.3 Arterial Circulation: Extracellular Matrix (ECM) Proteins and Associated 
Mechanical Properties 
Compared with the highly compliant venous circulation, arteries have significantly higher 
elasticity, reversible recoil, and resilience at low strains.[5] These properties allow the 
arterial circulation to act as a pressure reservoir, to ensure that blood flows distally 
especially during diastole. However, the mechanical properties vary during alternative 
loading conditions and relate to the composite nature of arteries facilitating anisotropic 
mechanical responses. The classical arterial stress-strain relationship is a non-linear J-
shaped curve possessing a low stiffness at low strains while transitioning exponentially to 
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a stiffer material at higher strains as shown in Figure 2.2.[5, 12] As such, blood vessels do 
not possess simple elastic properties, as non-linearity is observed when distended. These 
mechanical characteristics are due to numerous extracellular components produced by the 
cells within the vessel layers that collectively comprise the ECM. Specifically, these 
mechanical characteristics are due to components mainly within the medial layer, 
especially collagen and elastin.[5] 
 
Collagen is a stiff, extracellular protein, possessing a high tensile strength of approximately 
1.0×109 N/m2, whose concentration is highest in the tunica adventitia.[13] In the unloaded 
condition, collagen assumes a “crimped” state yet when load is applied, additional collagen 
fibers will assume a greater proportion of the load-bearing and re-align in the direction of 
the applied stress.[14, 15] It was believed that the load-bearing ability of collagen in the 
medial layer begins at higher stresses until recently whereby Chow et al. [16] proposed that 
medial collagen may be engaged from the onset of strain. Yet, it is the recruitment of 
additional load-bearing in parallel with the high tensile strength of collagen that makes the 
protein an ideal structural support for protection against aneurysmal development and the 
potential for vessel wall rupture, as the artery becomes stiffer as the strain increases. 
However, collagen itself does not impart elasticity and it is elastin, an amorphous 
constituent within the ECM, that provides this mechanical property. 
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Figure 2.2: Nonlinear mechanical behavior of an artery. A: average circumferential stress 
versus stretch ratio. B: circumferential incremental elastic modulus (Einc) versus stretch 
ratio. Einc was calculated by determining the local slope of the stress-stretch ratio 
relationship in Fig. A. Data shown is for adult mouse aorta.[5] Used with permission from 
the Publisher. 
 
Elastin exists within a composite of numerous ECM proteins that collectively are termed 
as elastic fibers.[17] Approximately 90% of the elastic fibers have been shown to be derived 
from elastin.[18] Intracellularly, elastin is transcribed as a 60-70 kDa tropoelastin precursor 
that contains numerous hydrophobic domains.[17] The transcriptional process is 
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developmentally regulated, with highest activity during late fetal and early neonatal period 
with minimal activity in adulthood due to post-transcriptional mechanisms at the 
downstream developmental stages.[19, 20]Additional segmental regulation occurs during 
these periods with the tissue-expression of elastin mainly being restricted to areas that 
undergo repetitive stresses.[21] When translated and excreted from the cell, tropoelastin 
becomes cross-linked at the cellular membrane by lysyl oxidase and the newly cross-linked 
structure is termed as elastin.[17] The aggregation is aided by the numerous hydrophobic 
domains which facilitate coacervation of the elastin subunits and promote the formation of 
strong desmosine and isodesmosine cross-links that provide the protein with its mechanical 
properties.[17, 22] The aggregates transfer to pre-existing micro-fibrils within the extra-
cellular space, whereby the major component of the micro-fibrils, fibrillin-1, serves as a 
scaffold for elastin deposition.[17, 23] The assembling of the composite continues to increase 
in size as the elastin coalesces. The assembly process of tropoelastin to elastin and 
interaction with the pre-existing micro-fibrils is shown in Figure 2.3.  
 
While elastin possesses a low tensile strength of approximately 4.6×105 N/m2, it functions 
best to provide high resilience to the artery with a contributory low stiffness.[13] Chow et 
al.[24] have demonstrated that maximal elastin engagement within the medial layer is 
reached at approximately 20% strain. Elastin is engaged at these low strains to allow for 
slight distensibility of the arterial wall to accommodate increases in blood volume during 
the cardiac cycle.  
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Figure 2.3: A. Assembly process of elastic fibers beginning at tropoelastin secretion and 
association with the cellular membrane where cross-linking occurs by lysyl oxidase. B. 
Silver stain (van Gieson) indicating that elastin is most evident within the medial layer of 
the vessel wall.[25] Used with permission from the Publisher. 
 
As mentioned earlier, the medial layer contains numerous SMCs in a lamellar organization 
interlaced with elastic fibers. The geometry of the tunica media aids in accommodating the 
cyclic circumferential strain due to the cardiac cycle. The developing wall stress during 
systole is uniformly distributed on the vessel wall due to the residual stress being greater 
than zero and studies have suggested that this effect can be mainly attributed to elastin 
within the medial layer.[26, 27]At low stresses, the elastic lamellae become more aligned and 
taut yet the collagen alignment is more gradual and activated at much higher stresses. 
However, during disease states, the underlying structure will be significantly altered. 
Various pathologies, including age-induced degeneration, atherosclerosis, and 
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hypertension can influence the integrity of the fibers and alternative mechanical properties 
will be observed.[15, 28] 
 
2.2 Coronary Arterial Circulation 
The coronary arterial circulation is a collection of mainly muscular arteries that begin at 
the sinus of Valsalva, where the ascending aorta gives rise to the right and left coronary 
arteries (RCA and LCA, respectively) from its right and left sinus openings.[29] The RCA 
and LCA will give rise to branches that will supply the entire myocardium. The LCA arises 
from the left aortic sinus and gives rise to the left circumflex artery and the anterior 
interventricular artery (left anterior descending; LAD). The RCA arises from the right 
aortic sinus and progresses laterally along the right side of the heart to give rise to vessels 
that mainly supply the right ventricle. In 90% of individuals, the RCA gives rise to the 
posterior interventricular artery: termed a right-dominated coronary circulation. Using 
arteriograms, Dodge et al.[30] indicated that normal vessel diameters of the LCA, proximal 
LAD, and distal LAD are 4.5±0.5 mm, 3.7±0.4 mm, and 1.9±0.4 mm, respectively with 
similar values obtained for the RCA and derivatives. The relative sizes between the sexes 
appear to vary significantly as documented in numerous studies.[31, 32] That said, the main 
deviation between individuals is the alteration in the mechanical properties of the coronary 
circulation with age. Specifically, the elastin-collagen ratio decreases with age from 5.43 
to 2.57 in the LCA and 3.80 to 1.72 in the RCA.[31] The decrease in the ratio suggests the 
progression of stiffer arteries with age. However, ignoring the extremes of age, the typical 
mechanical profile of the coronary circulation is as follows: a burst pressure of 2000 mmHg 
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[33], a maximal circumferential strain reached at 20% distension[34], and a normal pressure 
exposure between 50-130 mmHg.[35] 
 
2.3 Coronary Artery Disease (CAD) 
Cardiovascular disease (CVD) represents the leading cause of mortality globally from 
which coronary artery disease (CAD) is the leading factor.[1, 36] The alarming trend is that 
the incidence and prevalence of CVD is increasing. In the United States, it is projected that 
approximately 40.5% of the population will be burdened with CVD and the associated 
costs are expected to exceed $800 billion by 2030.[37] With advances in healthcare, the 
morbidity of the disease and its complications are likely to parallel this trend in augmented 
prevalence as individuals live longer lives. 
 
The main instigating factor in the development of CAD is atherosclerosis, a progressive 
disease characterized by gradual lumenal narrowing of blood vessels leading to 
compromised distal blood flow and tissue perfusion which results in potential ischemic 
complications.[38] The pathology increases in prevalence with age due to the progressive 
nature of the disease and repeated exposure to mostly modifiable risk factors. A main risk 
factor are increased levels of cholesterol and low-density lipoprotein (LDL), whereby the 
LDL functions to bring cholesterol and phospholipids to the peripheral cells and tissues 
rather than back to the liver for recycling as high-density lipoprotein facilitates.[39] 
Normally, LDL circulates within the plasma at low concentrations yet can be elevated due 
to a poor diet and diabetes, among other factors.[38, 40] If the endothelium is damaged, which 
is likely with hypertension and smoking, then LDL can accumulate within the sub-
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endothelial space within the tunica intima. The resultant response, and the basis of the 
pathogenesis of atherosclerosis, is the “response to injury” phenomenon which is an 
immune mediated reaction to cope with the lipid insult and endothelial damage.[41] Resident 
tissue macrophages within the sub-endothelial layer attempt to phagocytose and remove 
the LDL. However, numerous free radicals and potential apoptotic debris are produced 
which facilitate the oxidation of LDL within the layer.[38] As the macrophages repetitively 
ingest the oxidized LDL, they transition in morphology to become foam cells. The 
pathology and lumenal narrowing becomes exacerbated by endothelial damage and the 
ability of oxidized LDL to act as a pro-inflammatory and adhesive mediator to circulating 
monocytes.[38] 
 
The tunica intima has additional functions pertaining to anti-thrombotic activities under 
normal homeostatic conditions. The ECs are able to secrete numerous factors such as nitric 
oxide (NO) and prostacyclin (PGI2) which attempt to mitigate adhesion and promote 
vasodilation. The initial sign of endothelial damage is a decrease in the levels of NO 
produced which consequently leads to lumenal narrowing which facilitates a greater 
concentration of circulating clotting and inflammatory factors that can interact with the 
endothelium.[42] It is the integrity of the endothelial lining that is paramount as the sub-
endothelial matrix is highly thrombogenic in vivo with collagen and von Willebrand factor 
being able to interact with platelets. The damaged endothelium promotes the expression of 
specific adhesion molecules that are able to attract leukocytes to the area of damage such 
as P-selectin. An inflammatory cascade ensues whereby a fibrous plaque develops that 
attempts to cover the area of endothelial damage yet it will encroach and challenge the 
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integrity of the arterial lumen.[38] The response impacts the medial SMCs and the 
organization of elastin and other ECM proteins as SMC proliferation and protein 
production is stimulated. The resultant disorganization of the fibers further augments the 
stiffness of the blood vessel.[43] New tropoelastin may be secreted, yet it will not possess 
the same arrangement and thus the mechanical properties of the arteries will be 
significantly altered, especially as increased collagen is deposited due to the inflammatory 
process. 
 
The patency of the coronary arterial circulation is essential to ensure sufficient perfusion 
to the myocardium. Coronary artery occlusion follows a gradual course initially 
characterized by stable angina which leads to unstable angina and ultimately the potential 
for myocardial infarctions. The classification of the varying states is based on the degree 
of vessel occlusion. Rarely, blockages occur as a result of an embolus and are usually 
associated with atherosclerotic plaques. With higher occlusion percentages, individuals 
begin to complain of exertional dyspnea as the decrease in lumenal diameter compromises 
myocardial perfusion resulting in the lack of sufficient oxygenation.[44] With progressive 
occlusion, a myocardial infarction may occur which is characterized by a massive 
compromise in cardiac output and potential conduction disarray which leads to death. 
 
2.4 Therapeutic Interventions for CAD 
The initial therapeutic approach should be centered on prophylaxis through lifestyle 
modifications and pharmacological therapy. The treatment is based on attempting to reduce 
myocardial oxygen demand, which beta-antagonists can provide, or to increase the caliber 
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of the coronary vessels and improve exercise tolerance, which is the indication for nitro-
dilators. Additionally, aspirin or clopidogrel may be recommended to ease the concern of 
potential thrombi causing distal ischemia and complications. Unfortunately, the efficacy of 
lifestyle modifications and pharmacological therapy suffers from poor patient 
compliance.[2] More invasive interventions may be required if these techniques fail. 
 
In the non-surgical setting, the approach is centered on revascularization of occluded 
coronary vessels and can be accomplished most commonly with percutaneous coronary 
interventions (PCI) which include balloon angioplasty and coronary stenting. PCI entails 
the insertion of a wire or catheter, usually into the radial artery, that is guided via imaging 
to the site of the coronary occlusion.[45] A meta-analysis comparing the efficacy of PCI 
versus conservative pharmacological therapy in chronic stable CAD indicated that PCI fails 
to offer any benefit in the management of these patients and may have additional risks.[46] 
The main concerns with PCI are the potential for stent restenosis due to increased 
disorganized cellular proliferation within and around the stent and the development of 
thrombus formation. It has been shown that the main response to the procedure is a 
significant increase in intimal thickening.[47] Balloon angioplasty has been shown to have 
a 30-60% risk of re-occlusion of the vessel whereas bare metal-stents have an approximate 
16-44% risk in the development of restenosis.[48] To reconcile these risks, drug-eluting 
stents were developed, however complications can still occur in 3-20% of patients due to 
allergic reactions, granulomatous inflammation, and neo-intimal thickening.[49] With the 
development of more unstable ischemic inducing states, surgical interventions are 
considered as more potent re-vascularization strategies. 
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The standard surgical intervention is the coronary artery bypass graft (CABG). The 
procedure is based on transferring another vessel to replace the diseased artery. Most 
commonly, autografts are used such the great saphenous vein (GSV) or internal thoracic 
artery. However, a common occurrence is the presence of co-morbidities that make these 
vessels unusable or previous harvests have already removed them. Specifically, the GSV 
is usually found to be pathological when harvested, which emphasizes the need for 
consideration of other allogenic sources.[50] It is possible to harvest vessels from other 
donors or animals, yet significant immune-mediated issues arise due to their inherent 
thrombogenicity which has been shown to decrease the patency of the graft within a short 
time-frame post-operative in many patients.[51] Unfortunately, those with CAD are likely 
to have multi-vessel involvement. A recent meta-analysis comparing PCI to CABG for 
those with multi-vessel disease indicated that while CABG resulted in a slightly higher 
incidence of strokes, they did reduce the need for future re-vascularization and decreased 
long-term mortality.[52] A possible reason for the long-term advantageous use of CABG is 
that it may provide a more natural and tailorable environment for the cells to interact with. 
However, for small diameter graft replacements, no ideal solution exists as of yet and 
synthetic grafts produced in vitro are attempting to address this urgent clinical need. 
 
2.5 Vascular Tissue Engineering (VTE) 
2.5.1 Overview  
Vascular tissue engineering (VTE) attempts to mimic the native vessel architecture and 
fabricate a mechanical analogue of the vessels that will be conducive to cell viability and 
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growth potential while maintaining long-term lumenal patency. In blood vessel tissue 
engineering, the goal is to fabricate a tissue that is mechanically competent and biologically 
responsive in a process that is highly reproducible and consistent. The creation of such an 
analogue is termed a tissue engineered blood vessel (TEBV). The classical paradigm of 
VTE involves the growth of cells in two-dimensional (2-D) culture and subsequent seeding 
onto a three-dimensional (3-D) substrate for maturation. Ideally, maturation will occur in 
a bioreactor to mimic the native hemodynamic forces the cells are exposed to in vivo. The 
VTE process description for the fabrication of a TEBV is outlined in Figure 2.4. 
 
Figure 2.4: Process description for vascular tissue engineering (VTE). The overall 
approach is to harvest cells from patients, expand them in culture and seed them to a 3-D 
scaffold for maturation and remodeling in a bioreactor.   
 
 
2.5.2 Cell Source 
The cells utilized for VTE should reflect those found in native vessels, being some 
combination of fibroblasts, SMCs, and ECs that populate the three component vessel 
layers. ECs provide potent signaling to the underlying SMCs within the vessel which can 
direct ECM production and angiogenesis; the latter being highly important given the mass 
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transfer limitations of oxygen when vessel wall thickness is increased.[53] An intact 
endothelium significantly reduces the thrombogenicity of the graft at the early implantation 
stages – especially if seeded initially with venous ECs which have been shown to be less 
thrombogenic than arterial cells.[54, 55] Additionally, EC capture and seeding can be 
enhanced through the utilization of peripheral whole blood (PWB) as it contains numerous 
endothelial precursor cells that possess the capacity to differentiate into ECs if the correct 
milieu is provided.[56] For instance, the presence of a monolayer lining of ECs was observed 
when PWB was added to a decellularized allogenic scaffold.[57] Interestingly, when a graft 
is implanted into a patient, ECs have been shown to re-populate the lumenal lining in vivo 
with staining confirming the original seeded cells were replaced by native cells within an 
acute time-frame.[58] This suggests that vascular grafts may not necessarily need ECs when 
implanted given the ability of the ECs to re-populate the graft in vivo. However, if this 
were to occur, anti-platelet and anti-coagulative therapy should be provided until 
endothelialization occurs for the patient to be at low risk of developing thrombosis.[59] 
 
Given the ability of ECs to re-populate the graft in vivo, the main challenge is how to best 
re-populate the graft with the cells that comprise the tunica media and adventitia.[60] Stem 
cells have emerged as a viable option as a cell source due to their potential to differentiate 
into SMCs. Bone-marrow mesenchymal stem cells, adipose derived stem cells, and human 
umbilical cord derived stem cells have shown the ability to express vascular SMC (vSMC) 
protein markers in vitro and mimic SMC-like ECM production.[61, 62] Specifically, 
mesenchymal stem cells are a preferred choice due to their ability to be expanded in culture 
and avoid immune-mediated responses while maintaining multi-potency and easy access 
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for harvesting.[63] While promising, studies are mixed in regards to the adverse effects in 
vivo with the use of mesenchymal stem cells which may limit their use until safety can be 
ensured.[64] Additionally, while stem cells can be coaxed into differentiating down a vSMC 
pathway, given the complexity of the process, a reasonable concern is the extent of the 
differentiation.[65] 
 
As the differentiation process has not been optimized in vitro, the simplest way to ease this 
concern would be to utilize primary SMCs and fibroblasts - especially when attempting to 
investigate signaling pathways within grafts. However, primary SMC lines have been 
shown to have variable responses in culture that relate to the donor source.66 SMCs sourced 
from older donors produce less collagen and elastin and have less proliferative capacity 
than their juvenile counterparts.[66, 67] Regardless of age, primary SMCs show a limited 
capacity for proliferation in vitro, where typically 10-30 population doublings occur prior 
to senescenece.[67] While stem cells are more robust, there exists ways to circumvent the 
growth retardation of vSMCs seen in 2-D culture. As an example, McFetridge et al. [68] 
demonstrated that bioreactor systems can induce SMCs to maintain their in vivo 
phenotypes. It is also possible that the utilization of higher initial seeding densities can 
circumvent the need for numerous population doublings to increase ECM production. 
 
2.5.3 Scaffolds 
The ideal scaffold is expected to mimic the geometry of the tissue to be fabricated and 
provide correct clues to the cells that are conducive to growth and ECM production. The 
scaffold should initially allow for suitable attachment and anchorage of the cells followed 
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by proliferation without a cytotoxic or inhibitory effect. The ideal scaffold candidate would 
therefore be native ECM itself, and this can be made possible through the use of 
decellularized scaffolds. The native ECM provides a rich source of proteins such as 
fibronectin that cells can interact favorably with the matrix.[69] However, decellularization 
procedures usually requires the use of detergents and proteases that may disrupt the normal 
architecture of the ECM and dislodge potential signaling and attachment components.[70] 
The decellularization procedure generally produces variable mechanical change in the 
scaffold, usually generating weaker grafts.[70] Since collagen and elastin are essential for 
the mechanical properties of arteries, their use has been investigated as a comparable option 
to that of decellularized scaffolds. However, it has been found that collagen itself may be 
a poor scaffolding material as it loses mechanical strength and stability upon hydration in 
addition to potential immune-mediated reactions and disease-risk when extracted from 
animal sources.[71] Recombinant technology is attempting to produce collagen, yet the 
process remains to be optimized and is not currently a viable option for VTE use.[70] A 
major issue with elastin-based scaffolds are their propensity to calcify in vivo which would 
mitigate the suitability of the scaffold as the mechanical properties are altered.[72] Another 
approach, which would allow more consistent optimization of the required mechanical 
properties, is the development of synthetic scaffolds. These scaffolds, if fine-tuned to 
match the required properties of the ECM, possess high viability to be mass-produced and 
available as an “off-the-shelf” option for surgical interventions.[73] Viable synthetic 
scaffolds include biodegradable polymers, such as polyglycolic acid (PGA), 
polycaprolactone (PCL), and derivatives synthesized via copolymerization with polymers, 
such as poly (lactic-co-glycolic acid), that aim to optimize degradation kinetics of the graft 
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in vivo.[74] The goal is to match the degradation rate in vivo with suitable ECM production 
without jeopardizing the mechanical properties as this occurs.[70]  
 
Equally important to the scaffold material is the fabrication method. Electrospinning has 
emerged as a promising option for VTE due its ability to facilitate the fabrication of 
nanofibrous matrices that mimic the topography of the ECM. The technique involves 
subjecting a polymer solution to a high voltage which is ejected through a capillary in a 
dynamic unstable manner at a controlled rate. Once ejected, the electrical force is greater 
than surface tension which creates nanofibrous polymer mats.[75] The solvent is evaporated 
as random fibers are deposited onto a grounded collecting plate. However, while the fibers 
mimic the native ECM in morphology, it is difficult to control the exact orientation of the 
fibers and a major limitation with electrospinning is a lack of suitable cell infiltration due 
to small pore sizes.[76] Another technique that directly addresses this issue is utilizing 
hydrogels as the scaffolding material. Hydrogels are composed of hydrophilic polymer 
chains that are cross-linked allowing for the gel to swell when placed in an aqueous 
environment without a loss of structure.[77] The gel matrix allows for suitable mass transfer 
of nutrients and gases and additionally offers a way to ensure suitable cell encapsulation.[78] 
However, a major limitation with hydrogels is their lack of mechanical integrity, especially 
when utilizing natural polymers compared to synthetic options.[79] Another fabrication 
method is that of solvent casting and particulate leaching (SCPL). The technique involves 
dissolving a polymer in a suitable solvent and forcing the developing viscous solution 
through a porogen bed to which the porogen is leached out in a solvent that does not 
dissolve the polymer. The resulting construct will have a porous structure with high overall 
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porosity at the macro and micro porous levels. However, SCPL offers limited control over 
the orientation of the pores and the overall pore interconnectivity.[80] That said, the benefit 
of SCPL is that there is a high control over overall porosity and thus cell infiltration. 
Overall, SCPL offers a simple fabrication process with high tunability in a fabrication 
method that is cost-effective.[81] 
 
2.5.4 Bioreactors 
The use of bioreactors allows for simulation of the native hemodynamic forces. Forces 
such as shear stress on the ECs and the pulsatile nature of the blood flow can induce 
signaling events. Specifically, these forces have been shown to induce growth and 
maturation of the cells significantly different than that of static culture.[82] The stimulation 
induces the SMCs to secrete more ECM proteins and has been associated with improved 
graft mechanical properties.[83] Mechanical stimulation additionally allows vSMCs to 
adopt phenotypes more akin to the in vivo environment which may further explain the 
reasoning to these grafts developing higher mechanical properties and improved patency 
when cultured within a bioreactor.[84, 85] 
 
2.6 Small-Diameter VTE: Challenges and Potential Solutions 
Synthetic grafts made from expanded polytetrafluoroethylene (ePTFE) and polyethylene 
terephthalate (PET, Dacron) work well for large diameter vascular graft replacements 
(>6 mm diameter) where the blood flow rate is high but results in small diameter coronary 
artery graft applications (<4 mm diameter) have been disappointing.[86-88] The main 
limitation with small diameter grafts is thrombosis which occludes the lumen and 
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exacerbates the pathologies the graft attempts to alleviate. A non-autologous vascular 
replacement will induce an immune response, yet the reaction may not necessarily be acute. 
Furthermore, if the mechanical properties of the graft are not matched with that of the 
native vasculature at the anastomotic sites, the generated turbulent flow induces an 
immune-mediated response that can result in lumenal occlusion.[89] These limitations 
prompted the field of VTE. Despite rapid advances made in this field, success has been 
limited due to significant knowledge gaps in our ability to control and coordinate cell 
phenotype and direct tissue formation, which is the ultimate goal for VTE.[90] Particularly, 
stimulating and understanding elastogenesis in VTE has been proven to be difficult.[3, 11, 91] 
It is understood that for a TEBV to be successful, it must incorporate elastin into the 
developing tissue construct to achieve the required overall viscoelasticity of the final 
tissue.[11, 92] It is possible that utilizing elastomeric scaffolds could be helpful for improving 
the elasticity of the engineered tissue. Indeed, the use of elastomeric scaffolds has resulted 
in more akin mechanical properties to that of the native arteries.[93, 94] There is optimism 
that a cell-free tissue engineering approach can be based on the use of such scaffolds.[95] 
Unfortunately, the approach relies on in vivo re-modeling and it can be expected that the 
results will be variable. Additionally, this technique relies on infiltration of native cells and 
an immune response to acquire the required remodeling.  Yet again, this may vary from 
host to host and might not be suitable for the small diameter vasculature.[96] As such, while 
the synthesis of elastomeric scaffolds improves the mechanical properties, there is a need 
to seed cells prior to implantation. Ideally primary human coronary SMCs (hcSMCs) that 
are responsible for producing elastin and assembling it to elastic fibers within the medial 
layer would be utilized. If elastin can be produced at high levels and assembled into fibers, 
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then the mechanical properties of TEBVs can be expected to increase. An avenue that can 
be taken is the use of factors that can stimulate elastogenesis. However, in addition to their 
impact on elastogenesis, these factors may influence the phenotype of the vSMCs.  
 
2.7 Vascular Smooth Muscle Cell (vSMC) Culture 
2.7.1 vSMC Phenotype 
vSMCs represent a dynamic cell line in which their phenotype is not terminally 
differentiated and rather exists as a continuum of states between synthetic and 
contractile.[97] During development, vSMCs begin in a highly proliferative synthetic state 
where ECM protein production is high. A transition occurs that decreases ECM production 
and increases intercellular myofilaments, a switch that facilitates the required contractility 
within blood vessel walls.[98] Studies have indicated that the transition can be bi-
directional.[99, 100] The phenotypic plasticity can vary along the arterial tree during normal 
homeostatic conditions due to the presence of alternative populations of vSMCs.[101] 
However, in vivo, the phenotypic plasticity is correlated with pathological events such as 
seen in atherosclerosis whereby the usual contractile vSMCs in the medial layer can 
migrate to the intima and become synthetic, promoting intimal thickening and hyperplasia 
– an undesirable outcome. The continuum between synthetic and contractile is classically 
characterized by the presence or absence of specific proteins.[97] The contractile state 
contains minimal rough endoplasmic reticulum and ribosomes indicating that its function 
is not related to extensive ECM protein synthesis.[101]  When the vSMCs are in the 
contractile state, they have a large volume fraction of myofilaments within their 
cytoplasm.[98] The contractile proteome of these cells indicate high expression of 
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contractile protein markers such as smooth muscle alpha actin (α-SMA), calponin, SM-
22α, and smoothelin.[101] De-differentiation into the synthetic phenotype is associated with 
a loss of these markers.[101] In addition to quantitative changes in the contractile protein 
markers, the modulation in phenotype is also associated with alternative rearrangements 
and realignments of the myofilaments.[102] Due to the lower level of protein secretion, the 
contractile vSMCs are denser and more fusiform in nature, a stark contrast to the expansive, 
broad, and fibroblast-like epithelioid morphology of the synthetic phenotype. When cells 
de-differentiate into a synthetic phenotype, a loss of the high volume of myofilaments, a 
disappearance (or reduction) of the contractile markers, and an increase in apparatuses 
promoting protein production have been observed. Specifically, elastin production is likely 
correlated with the synthetic vSMCs phenotype, yet there has been mixed results.[103, 104] 
In contrast to the contractile upregulation of vSMC protein specific markers, it is thought 
that the synthetic phenotype is characterized by a disappearance of the contractile markers. 
However, proteins such as L-caldesmon and meta-vinculin can be used to denote the 
synthetic state, yet marker specificity for the synthetic phenotype is not as specific as the 
contractile state.[105] 
 
2.7.2 vSMC Response to Microenvironments: 2-D vs. 3-D Culture 
Classically, most cell culture investigations have been performed on a 2-D surface yet this 
is an inaccurate representation of the in vivo environment. While 2-D culture is a quick and 
well-established culture system, it only provides a simplistic and limited substrate that cells 
can interact with. Within the ECM, cells are constantly exposed to varying topologies, 
gradients, and forces – all of which are difficult, if not impossible, to replicate in a 2-D 
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setting. It can be expected that cells will respond and behave differently when seeded in 2-
D and 3-D environments. When cultured in 2-D, most vSMCs are known to adopt a more 
synthetic phenotype compared to a contractile state usually seen in vivo.[101, 106] Yet, most 
early experimental designs considered vSMCs only in a 2-D environment, one that is stiffer 
than the native ECM found in blood vessels. Indeed, a major difference between 2-D and 
3-D is the stiffness of the underlying substrate. Recently, Timraz et al. [107] demonstrated 
that collagen-I gels with varying degrees of stiffness can influence vSMC phenotypic 
differentiation and protein secretion with the synthetic phenotype being inversely 
proportional to increasing the stiffness of the gels. However, the study investigated cellular 
responses when encapsulated in a collagen gel and when combined with various ECM 
proteins, such as fibronectin, which may influence the manner in which the cells interact 
and spread within the matrix as the supplemented factor concentration is increased. The 
exact experimental design for investigating how cells respond to variant stiffness in 3-D 
remains to be optimized. This may be due to designs that increase the cross-linking density, 
consequently increasing the propensity for cell-mediated proteolysis and subsequent 
migration.[108] A commonality between how the cells sense stiffness in 2-D and 3-D is 
through RhoA, a small GTPase that facilitates mechanotransduction. RhoA activation has 
been shown to be upregulated in 2-D culture and in atherosclerosis.[109] When RhoA is 
constitutively expressed in vSMCs in 3-D cultures, the state of vSMC differentiation has 
been shown to depend on the stiffness of the substrate and produced similar cytoskeletal 
effects seen in 2-D culture.[106] Upregulation of RhoA in vSMCs is associated with an 
increase in contractile SMC markers in 3-D.[106] While stiffness may have an effect on the 
phenotype, the 3-D environment additionally changes the mechanism in which the cells are 
27 
 
 
able to sense their surroundings. Using varying matrices, Hong et al.[110] demonstrated 
varying temporal differences in ECM expression in 3-D relative to 2-D with significant 
variability when alternative 3-D scaffolds were used. Work by Lin et al. [111] also 
demonstrated that hcSMCs seeded in 3-D expressed higher levels of elastin than in 2-D 
culture. However, when TGF-β1 was utilized to increase elastin, the up-regulated 
elastogenic effect was noticed only in 3-D and not in 2-D suggesting that the effect of TGF-
β1 in 2-D cultures may not translate to 3-D. Another biochemical factor that is elastogenic 
but not widely studied is retinoic acid which is a vitamin A derivative. Since this thesis 
focuses on retinoic acid, an expanded review is presented in the proceeding section. 
 
2.8 Retinoids 
2.8.1 Overview 
Retinoids are derivatives of vitamin A that are highly active during embryogenic 
development and have been shown to have a positive impact on elastogenesis. Four of the 
biologically active derivatives are retinol, retinal, 9-cis retinoic acid (9cRA), and all-trans 
retinoic acid (atRA).[112] While there are numerous metabolites, it is atRA which is the 
carboxylic acid form that has been shown to have the most potent biological activity.[113] It 
should be noted that there have been reports indicating isomerization potential between 
atRA and 9cRA intracellularly.[113] As a lipophilic molecule, the atRA concentrations 
within the plasma are low - ranging between 1-10 nmol/L.[113] Most in vitro experiments 
with atRA utilize the relevant therapeutic and physiological concentration, corresponding 
approximately to 1 μmol/L.[113] Due to its lipophilicity, a retinol binding protein (RBP) 
associates with atRA within the plasma and carries the molecule to target organs.[114] The 
28 
 
 
atRA is able to diffuse past the cellular membrane and an interaction can occur with a 
cellular retinoic acid binding protein (CRABP). There are two isoforms of CRABP, being 
I/II, though only CRABP-I has been shown to be relevant in vSMCs.[115] Binding to the 
CRABPs occur with high affinity and seems to increase the ability of atRA to be 
translocated to the nucleus.[116] Within the nucleus, the complex interacts with two subsets 
of nuclear receptors being the retinoic acid receptor (RAR) and retinoid X receptor 
(RXR)[113], to which there are 3 isoforms of each (α, β, and γ).[117, 118] Both receptors 
associate as a heterodimer that are bound to a retinoic acid response element (RARE) near 
specific target genes that normally act to repress transcription. Retinoids are able to bind 
to the RAR allowing for conformational changes to be induced that create positive 
transcriptional effects. Both 9cRA and atRA are able to bind to the RAR yet only 9cRA 
can associate directly with the RXR. However, the RXR itself has not been proven to have 
physiological relevance. An overview of the metabolism and subsequent processing of 
atRA is shown in Figure 2.5. 
 
Figure 2.5: Intracellular effects of atRA. After being transported through the plasma by a 
protein carrier, albumin, atRA translocates across the membrane and associates with the 
CRABPs that allow nuclear translocation and subsequent transcriptional effects.[113] Used 
with permission from the Publisher.    
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2.8.2 atRA Impact on vSMC Phenotype 
The current understanding of the effect of atRA on vSMC phenotype is that an anti-
proliferative and differentiated state is induced. Interestingly, atRA is being investigated 
for its role is preventing intimal thickening and restenosis following PCI.[4] The elevated 
levels of contractile makers have been associated with atRA possessing potential negative 
effects on growth and cellular proliferation in human tissue culture. Axel et al.[119] found 
that in a dose-dependent manner, atRA decreases both proliferation and migration. The 
ability to produce the latter effects may be attributed to a retinoid-inducible tissue trans-
glutaminase (ttG).[120] Recently, in vivo experiments confirm that atRA can inhibit vSMC 
proliferation and promote contractile marker expression via upregulation of Kruppel-like 
Factor 4 (KLF4), a zinc-finger transcription factor.[121]  KLF4 activation has been shown 
to activate p53 to inhibit vSMC proliferation.[122] Knockdown studies of KLF4 mitigated 
the atRA mediated increase in contractile protein markers being α-SMA and SM-22α.[123] 
In rat vSMCs, atRA has been shown to increase the levels of contractile markers such as 
α-SMA.[124] The increase in these markers was associated with a stimulation in protein 
kinase C-α activity.[124]  However, it is not intracellular interference alone that atRA exerts 
its anti-proliferative effect, as it has been shown to influence ECM production. Perlecan 
sulfate is a large proteoglycan within the ECM that has been shown to have anti-
proliferative properties. When transgenic mice were engineered to be deficient in perlecan 
sulfate expression, the atRA mediated anti-proliferative effect was depressed.[125] That 
said, most of the above studies occurred in 2-D culture. The phenotype adopted by vSMCs 
in response to atRA treatment may be dependent on the initial state of the cells.[126] The 
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different responses obtained in early investigations may be due to the source of vSMCs 
and the experimental design. 
 
2.8.3 atRA Impact on Elastin Expression  
The effects of atRA seems to be tissue-dependent with pleiotropic impact.[113] In terms of 
elastogenesis, atRA has been shown to have potent impact on the pulmonary and arterial 
circulations and is associated with dermal elasticity.[127-129] The earliest studies suggesting 
atRA may increase elastin occurred in pulmonary lung fibroblasts based on observations 
that elastogenesis within the alveolar septa correlated with atRA levels during brief periods 
in postnatal life.[130] For the pulmonary circulation, elastin is essential for lung compliance 
and proper breathing mechanics. Indeed, deletions in RARs, specifically RARγ, have 
corresponded to reduced elastin and alveolar numbers.[131] Similar pathological 
manifestations occur within the vasculature when atRA signaling pathways are interfered 
with. Pathologies that result from low retinoid levels include an increased mortality from 
CAD.[132] Within the arterial tree, the derivatives of vitamin A with the greatest elastogenic 
impact are 9cRA and atRA.[133] In aortic SMCs harvested from 18-day old chick embryos 
and cultured on 2-D surfaces supplemented with atRA, elastin synthesis increased in a 
dose-dependent manner while cell number was decreased compared to the control.[133] This 
suggests that if atRA is to be used in VTE, higher cellular seeding densities should be 
utilized. 
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2.8.4 atRA in Combination with Ascorbic Acid: Impact on Elastin 
Ascorbic Acid (AA) is added to cell culture experiments due to its potent effect on collagen 
synthesis in numerous cell types.[134-136] However, supplementation with AA in 2-D culture 
attenuates elastogenesis in a concentration dependent manner. AA can influence 
elastogenesis at both the transcriptional and post-transcriptional stages by reducing total 
transcript number and tropoelastin mRNA stability.[137] There may be an interplay between 
the two factors on elastogenesis in long-term cultures. While AA can increase the 
mechanical properties of the engineered tissue, the resulting increase in stiffness due to a 
lack of elastogenic stimulation may result in a vessel that does not mimic the in vivo 
scenario.[138] While atRA was added to mitigate the loss of elasticity, the combination of 
both seemed to have a complex impact on elastogenesis. 
 
2.9 Study Rationale and Objectives 
Within the VTE field, a major limitation is the inability to properly recapitulate the 
mechanical properties of a native tissue. Specifically, in vitro elastogenesis has proven to 
be difficult while collagen production can be sufficiently stimulated. It is necessary to 
increase both collagen and elastin synthesis to ensure the engineered vessel has suitable 
mechanical properties. As the goal would be to increase elastin expression, biochemical 
factors can aid in stimulating elastogenesis. Specifically, we suspect that atRA can increase 
elastin expression in 3-D cultures. However, as there is a need to promote collagen 
synthesis too, AA and atRA may have significant effects on the phenotype of vSMCs that 
could be relevant to elastogenesis. In doing so, better understanding of the interaction 
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between AA and atRA may lead to the engineering of functional vascular substitutes. In 
view of the above, the objectives of this study were to: 
i) Fabricate and characterize PCL scaffolds with suitable porosity conducive to 
cellular infiltration and proliferation and 
ii) Evaluate elastogenesis when hcSMCs are seeded on PCL scaffolds and treated with 
AA and atRA individually or in combination 
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Chapter 3 – Materials and Methods 
 
3.1 Materials 
ε-Polycaprolactone (PCL; Mn=80,000 Da) was used to fabricate the 3-D scaffolds and was 
obtained from Sigma Aldrich (Oakville, ON, Canada). All solvents used to dissolve the 
PCL pellets were obtained from Caledon Labs (Georgetown, ON, Canada) and included 
chloroform (CHCl3), ethyl acetate (EtOAc), and tetrahydrofuran (THF). Ammonium 
chloride (NH4Cl) was supplied by Caledon Labs and was utilized as the porogen for the 3-
D scaffolds. Cell culture experiments were conducted on primary hcSMCs in Medium 231 
supplied by Life Technologies (Burlington, ON, Canada) and on immortalized NIH-3T3 
fibroblasts in DMEM obtained from Lonza Walkersville Inc. (Walkersville, MD, USA). 
Medium 231 was supplemented with 5% penicillin G and streptomycin sulfate (P/S), 
insulin-like growth factor (IGF), and basic fibroblast growth factor (bFGF). DMEM was 
supplemented with 10% fetal bovine serum (FBS) and 5% P/S. All components added were 
obtained from Life Technologies. Cellular washing steps were conducted in Hank’s 
Balanced Salt Solution (HBSS) supplied by Life Technologies. L-ascorbic acid (AA) and 
all-trans retinoic acid (atRA) were obtained from Sigma Aldrich. For cell fixation and 
immuno-histochemistry, a 4% paraformaldehyde solution in diH2O was prepared from 
paraformaldehyde obtained from EMD Chemicals (Gibbstown, NJ, USA). 
Immunostaining utilized Alexa Fluor® 488 Phalloidin and DAPI (4’,6-diamidino-2-
phenylindole) supplied by Life Technologies. Mounting medium was obtained from 
Vector Laboratories (Burlington, ON, Canada). For qPCR, initial RNA isolation occurred 
utilizing Trizol® Reagent supplied by Life Technologies. Glycogen and iQ™ SYBR® 
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Green Supermix, used in the RNA purification and cDNA synthesis respectively, were 
obtained from Bio-Rad (Mississauga, ON, Canada). RNA work utilized a NanoDrop Lite 
Spectrophotometer obtained from Thermo Scientific and a C1000 Touch™ thermal cycler 
(CFX96™ Real-time system) supplied by Bio-Rad. Protein quantification for western 
blotting was based on the construction of a standard curve utilizing bovine serum albumin 
(BSA) supplied by Sigma Aldrich. Protein quantification was completed using the 660 nm 
protein assay supplied by Thermo Scientific (Ottawa, ON, Canada). For western blotting, 
monoclonal (α-SMA and GAPDH) primary antibodies were obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA) and EMD Millipore (Temecula, CA, USA) respectively. 
Polyclonal primary antibody against elastin was supplied by EPC (Owens, MO, USA). 
Secondary anti-rabbit and anti-goat HRP-conjugated antibodies were supplied by Santa 
Cruz Biotechnology. SuperSignal® West Pico Chemiluminescent Substrate was supplied 
by Thermo Scientific (Rockford, IL, USA). ChemiDoc™ XRS+ and ImageLab™ software, 
obtained from Bio-Rad, were utilized to image and quantify the membranes respectively. 
 
3.2 Methods 
3.2.1 Scaffold Fabrication via Solvent Casting and Particulate Leaching (SCPL) 
Tubular PCL scaffolds were fabricated using a solvent casting and particulate leaching 
(SCPL) method based on previous established protocols in our laboratory.[139] Briefly, 
NH4Cl particles were mechanically processed using a mortar and pestle prior to passing 
through graded sieves to obtain porogen particle sizes between 180-210 μm. The collected 
particles on the 180 μm sieve were re-sieved once, to ensure they fell within the desired 
range. PCL pellets were dissolved in various solvents (CHCl3, EtOAc, THF) at 40 ⁰C and 
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varying concentrations, ranging from 10-30% w/w. To prepare the porogen bed, the NH4Cl 
particles were packed into the annulus of a glass tube with a central mandrel. The polymer 
solutions were then infiltrated over the porogen bed using a pressure differential created 
by applying vacuum to the inferior aspect of the porogen bed. The glass rod was then 
removed from the apparatus and left upright in a fume hood for 2 hours prior to removal 
of the scaffolds from the glass rod. The scaffolds were kept for approximately 12 hours, to 
dry and allow for solvent evaporation, in the fume hood prior to placement into diH2O. The 
tubular scaffolds were cut into small rings cut using a microtome. Rod-like porous 
scaffolds were also fabricated by removing the mandrel during the porogen packing. The 
SCPL apparatus is shown in Figure 3.1. 
 
 
 
Figure 3.1: Solvent casting and particulate leaching apparatus. The digital images shown 
are the tubular scaffolds fabricated using the apparatus.  
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3.2.2 Scaffold Characterization 
3.2.2.1 Scanning Electron Microscopy (SEM) 
A scanning electron microscope (2-2600N, Hitachi, Japan) was utilized to assess the 
fabricated scaffold morphology. The scaffolds were sectioned into pieces of varying 
lengths to investigate the lumenal, ablumenal, and cross-sectional morphologies. The 
scaffolds were cut using a microtome and affixed via carbon tape to studs prior to gold 
sputtering and subsequent imaging.  
 
3.2.2.2 Microcomputed Tomography (micro-CT) 
Scaffolds were sectioned with a microtome into slices 4 mm in length. Imaging occurred 
using the eXplore Locus SP (GE Healthcare, Canada). Two different batches of scaffolds 
were scanned at a voxel resolution of 11 μm, using an integration time of 1700 ms per 
frame with 15 views per frame over 900 views encompassing 360⁰. The x-ray tube voltage 
and current were set at 80 kVp and 90 μA respectively. The 2-D images obtained were 
compiled to generate 3-D representations of the scaffold architecture. A commercially 
available trabecular bone analysis software (MicroView version Viz+2.0, GE HealthCare) 
was utilized to analyze the 3-D images. Data analysis considered overall porosity, pore 
size, surface area to volume ratio, and strut thickness. 
 
3.2.3 Cell Culture Conditions 
Primary hcSMCs, between passage 4-8, were cultured in Medium 231 supplemented with 
bFGF, IGF, and 5% P/S. NIH-3T3 fibroblasts, between passages 6-15, were cultured in 
DMEM supplemented with 10% FBS and 5% P/S. Cell culture occurred within a 37 ⁰C 
37 
 
 
sterile incubator at 5% CO2. When factor addition was considered, all media changes 
occurred daily in the dark. 
 
3.2.4 Scaffold Preparation for Cell Culture 
Cylindrical scaffold sections, approximately 1 mm in length, were affixed with silicone 
grease. 10 scaffolds per 3.5 cm culture dish or 1 scaffold per 96-well plate were used. The 
scaffolds were immersed in EtOH overnight under UV light at RT in a sterile fume hood. 
The EtOH was aspirated and replaced with HBSS for pre-conditioning at 37 ⁰C. Three 
aspirations of the HBSS were completed over the course of 12 hours to ensure removal of 
any residual EtOH. 
 
3.2.5 2-D and 3-D Culture 
Experiments in 2-D were carried out with hcSMCs seeded at densities of 250,000 cells/ 3.5 
cm diameter dish. L-AA and/ or atRA addition occurred once the cells reached confluency 
and was termed day 0 in biochemical factor related experiments. Experiments in 3-D were 
carried out on hcSMCs and NIH-3T3 fibroblasts. The hcSMCs were seeded at a density of 
450,000 cells/ scaffold. The NIH-3T3 fibroblasts were seeded at a density of 900,000 cells/ 
scaffold. Cells were allowed 24 hours for attachment prior to addition of L-AA and/ or 
atRA which was termed day 0 in biochemical factor experiments. 
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3.2.6 Cell Viability and Proliferation Assays 
3.2.6.1 MTT 
NIH-3T3 fibroblasts and hcSMCs were seeded onto 20%, 25%, and 30% PCL scaffolds 
prepared w/w in EtOAc. Cell culture occurred for 4 and 7 days at which time the media 
was aspirated and the cells were washed 1x gently in HBSS prior to the addition of 0.05% 
Trypsin-EDTA solution and incubation at 37 ⁰C for 3 minutes. The solution was 
centrifuged and the pellet re-suspended in phenol red free medium. Addition of the MTT 
reagent, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, was added to each 
well at a final concentration of 1.10 mM. The mixture was incubated at 37 ⁰C for 1 hour 
proceeded by the addition of an equal volume of SDS (10% w/v in diH2O) and the 
absorbance was read at 570 nm by a plate reader. The phenol red free medium was added 
to each plate as a blank. 
 
3.2.6.2 DNA Quantification 
The proliferative capacity of hcSMCs was investigated using the CyQUANT® cell 
proliferation assay, obtained from Thermo Scientific, and following the manufacture’s 
protocol. Briefly, primary hcSMCs were seeded at a density of 500 cells/ scaffold in 96-
well plates on 30% PCL scaffolds prepared w/w in EtOAc. After either 4 or 7 days, 0.05% 
Trypsin-EDTA solution was added and the scaffolds were incubated at 37 ⁰C for 3 minutes. 
Scaffolds were centrifuged for 5 minutes at 4000 rpm and the supernatant removed prior 
to cellular pellet freezing at -80 ⁰C. CyQUANT GR dye/ cell-lysis buffer was added to the 
pellets and fluorescence was read at 562 nm. A cell number standard curve allowed for 
quantification of growth over time. 
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3.2.7 Immunofluorescence Staining and Confocal Imaging in 3-D Culture 
Cell cultures with primary hcSMCs on 3-D porous scaffolds were stained for F-actin and 
nuclei prior to imaging. Cells were fixed in 4% Paraformaldehyde for 1 hour at RT prior 
to cell permeabilization with 0.5% Triton X-100 for 10 minutes in 1x PBS. Following 
permeabilization, 2x washing steps for 5 minutes were completed in 1x PBS. Incubation 
for 1 hour at RT with diluted Alexa Fluor® 488 Phalloidin (1:50) in 1% BSA/PBS followed 
with 2x subsequent washing steps in 1x PBS for 5 minutes. Incubation with secondary 
antibody occurred for 1 hour at RT followed by 1x wash in 1x PBS for 5 minutes. DAPI 
staining was done for 10 minutes at RT prior to 1x wash in 1x PBS for 5 minutes. Scaffolds 
were affixed to glass microscope slides in mounting medium whereby spacers held the 
samples in place. A Zeiss LSM 510 confocal microscope (Carl Zeiss, Germany) was 
utilized in the imaging of the cells on the 3-D scaffolds. 
 
3.2.8 RNA Isolation and Gene Expression Studies Using Real-Time PCR (qPCR) 
Analysis 
Real-time polymerase chain reaction (qPCR) was used to quantify mRNA expression of 
GAPDH and elastin in primary hcSMCs seeded in 2-D culture. Total RNA was extracted 
via Trizol® Reagent to which 0.50 μg glycogen was added during the purification as 
described in the manufacture’s protocol. The RNA pellet produced during the purification 
procedure was re-suspended in 20 μL dcpH2O and quantified using a NanoDrop Lite 
Spectrophotometer. cDNA synthesis utilized 1 μg of total RNA, SsoAdvanced™ SYBR® 
Green Supermix, and 20 μM of GAPDH and elastin forward and reverse primers. The 
primers were as follows: GAPDH forward primer, 5’-GTT GGT CTC TGA CTT CAA 
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CA-3’, and reverse primer, 5’-GTT GCT GTA GCC AAA TTC GTT GT-3’; elastin 
forward primer, 5’-AAC CAG CCT TGC CCG C-3’, and reverse primer, 5’-CCC CAA 
GCT GCC TGG TG-3’, were utilized.[140, 141] The qPCR protocol followed was specific for 
the SsoAdvanced™ SYBR® Green Supermix as per Bio-Rad. Samples were prepared in 
three replicates per experimental group and expression was normalized to GAPDH. Gene 
expression Macro Analysis Software was utilized for quantification. 
 
3.2.9 Protein Analysis Using Western Blotting 
A Lysis Buffer (LB) was prepared with final concentrations of 1x proteinase inhibitor 
cocktail, 1x PMSF, and 1x RIPA buffer all in diH2O. For 2-D culture, plates were washed 
in 1x ice-cold PBS 3x prior to direct addition of LB to the culture plates followed by 
scrapping and freezing at -80 ⁰C. For 3-D, the individual scaffolds were washed 3x in ice-
cold 1x PBS prior to freezing at -80 ⁰C. Once frozen, scaffold pieces were cut using a 
scalpel blade and added to LB and 3x freeze-thaw cycles occurred between -80 ⁰C and RT. 
All subsequent work ensured protein samples were kept at least at 4 ⁰C. Centrifuging 
occurred at 12,200 RPM at 4 ⁰C for 12 minutes. The supernatant was collected and diluted 
1:4 for protein quantification based on a BSA standard curve read at 562 nm. Resolving 
gels were prepared at 10% and stacking gels were prepared at 6%. Approximately 20-30 
μg of total protein was loaded into the gels with each sample being composed of a final 
concentration of 1x Laemmli Sample Buffer with 1% beta-mercaptoethanol. Samples were 
heated at 95 ⁰C for 5 minutes and briefly micro-centrifuged prior to loading. SDS-gels were 
run for 1 hour at 160 V. Transfer occurred for 1 hour at 90 V with numerous ice-packs to 
ensure the temperature was low on the nitrocellulose membranes submerged in a Tris-
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glycine buffer containing 20% methanol. Ponceau S staining was subsequently utilized to 
qualitatively assess transfer efficiency. Blocking the membrane occurred over 1 hour in a 
solution containing 5% skim milk powder and 0.55% tween-20 in 1x PBS. Primary 
antibody incubation occurred overnight at 4 ⁰C in incubation buffer consisting of 0.1% 
skim milk powder and 0.11% tween-20 in 1x PBS. Primary antibody dilutions were made: 
α-SMA (1:500), GAPDH (1:1000), and elastin (1:250). After overnight incubation, 3x 
washing steps in incubation buffer occurred prior to incubation for 1 hour with HRP-
conjugated secondary antibodies diluted (1:250) in incubation buffer. A further 3x washing 
steps in incubation buffer were completed prior to addition of the SuperSignal® West Pico 
Chemiluminescent Substrate. A ChemiDoc™ XRS system, from BioRad, was used to 
visualize the blots with further quantification occurring using ImageLab™ software. 
 
3.2.10 Statistical Analysis 
All protein quantification occurred using GraphPad Prism 5. Quantified data from qPCR 
and western blotting experiments was normalized to controls with no factor treatment in 
addition to GAPDH. Graphs were based on values obtained from three independent 
experiments. The data is displayed as mean ± standard deviation. The data was statistically 
analyzed by a one-way ANOVA proceeded by Tukey’s post hoc test or an unpaired 
Student’s t-test. P-values of <0.05 were considered to be statistically significant. 
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Chapter 4 – Results and Discussion 
 
4.1 Scaffold Characterization 
4.1.1 General Observations during Scaffold Fabrication 
An ideal scaffold would be of comparable topography to that of the native ECM and 
possess suitable porosity internally with lumenal and ablumenal surfaces conducive for cell 
infiltration. An essential corollary to this notion is that the scaffold must possess the correct 
micro-structure to allow for the required cell attachment and proliferation.[142] 
Additionally, the scaffold should ideally be biodegradable with the degradation rate 
matching cellular ECM production to maintain mechanical integrity. PCL has been shown 
to meet the above requirements, with its in vivo degradation products being non-toxic while 
possessing the ability to be enzymatically and hydrolytically degraded.[143, 144] However, 
PCL  degrades slowly (2-3 years) as the polymer is more so bioresorbable rather than 
biodegradable.[144, 145] This may be advantageous as it provides sufficient time for cells to 
regenerate their own ECM, if further in vivo remodeling is needed. That said, the optimal 
amount of time to match ECM production rates with biodegradation remains unknown.[146] 
 
Previous investigations using PCL have been focused on electrospinning applications 
except a few studies which investigated PCL utilizing the SCPL process. Given the 
limitations of cell infiltration with electrospinning[76] and the potential for the seeded cells 
to therefore sense a more 2-D environment[147], it was thought that SCPL would be more 
appropriate – especially when investigating cellular activity differences to biochemical 
factors in 2-D compared to 3-D. Since PCL has not been extensively fabricated by SCPL, 
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there was a need to study this fabrication process. The variables considered in the SCPL 
process are outlined in Table 4.1.  
 
Table 4.1: Variables considered for solvent casting particulate leaching (SCPL) process to 
fabricate PCL Scaffolds. 
 
Variables  
PCL concentration (w/w) 10, 15, 20, 25, 30% 
Solvent CHCl3, EtOAc, THF 
Hold time in the tube (hours) 1, 2, 4, 6, 12, 24 
Mandrel Materials Teflon™ and stainless steel 
 
Both tubular and rod-like scaffolds were fabricated. For the tubular scaffolds, a 4 mm 
mandrel was utilized and the resulting scaffold possessed an approximate 0.5 mm wall 
thickness to reflect the average size of a typical coronary vessel.[30] During scaffold 
fabrication, the scaffolds were kept upright in a glass rod for 2 hours before removing them 
from the mandrel and outer glass casing in order to evaporate part of the solvent and prevent 
scaffold damage. The 2 hour hold time in the glass rod was found to be optimal as longer 
times resulted in the scaffold hardening in the glass rod and thus was difficult to remove 
without damage. Scaffolds removed with hold times less than 2 hours were too weak and 
generally disintegrated upon removal. PCL concentrations greater than 30% were too 
viscous to be poured over the porogen bed and those less than 20% produced scaffolds with 
poor structural integrity and presented a challenge to consistently produce. Additionally, 
the fabrication of the cylindrical rod-like scaffolds were found to require longer wait times 
after removal from the scaffold fabrication chamber. This was likely due to the time needed 
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to evaporate the solvent and, perhaps, for the PCL to undergo some recrystallization which 
has been shown to generally result in an improvement of its mechanical properties.[148]  
 
Regardless of initial PCL concentration for the rod-like cylindrical scaffolds, if these 
scaffolds were inserted into the deionized H2O prematurely, the cross-sectional integrity 
was compromised and overnight incubation at RT was the optimal way to prevent this 
occurrence. An issue of structural/physical instability was observed in the rod-like 
cylindrical scaffolds at 10% and 15% concentrations whereby an unexpected hollow 
lumen-like structure was observed. This effect was seen with both hydrophobic (CHCl3 
and EtOAc) and hydrophilic solvent (THF) systems. Although a structurally stable PCL 
scaffold was not possible below a 20% concentration, Lin et al.[149] fabricated polyurethane 
scaffolds at 15% concentrations in dimethylformamide. It is likely that the molecular 
weight differences between these polymers represent one factor.  The extensive hydrogen 
bonding that exist within polyurethanes is also a factor since solution viscosity increases 
with increased intermolecular forces.[150] 
 
4.1.2 Scanning Electron Microscopy (SEM) 
As the 2 hour hold time in the glass tube was optimal for the scaffold fabrication process, 
this time was chosen for subsequent scaffold fabrications. The SEM images for the tubular 
scaffolds are presented in Figures 4.1, 4.2. and 4.3. The ablumenal and lumenal surfaces 
were examined for their porous morphology. It was thought that the SCPL process would 
produce ablumenal and lumenal surfaces that were porous which would be beneficial for 
cell seeding, infiltration, and mass transfer.[151] Additionally, having a more porous lumenal 
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surface has been shown to make grafts less thrombogenic when implanted.[152] As the 
porogen was in close proximity to the glass rod or central mandrel, this was thought to 
facilitate an easier leaching out of the porogen and thus ensuring surface porosity. The 
effects of the organic solvent used to prepare the solution and the PCL concentration on 
the morphology of the tubular scaffolds is shown in Figures 4.1 and 4.2 respectively.  
 
Figure 4.1: Ablumenal SEM images of 20-30% w/w PCL scaffolds fabricated using SCPL. 
PCL was dissolved in CHCl3 (A-C), EtOAc (D-F) and THF (G-I). Scale bar represents 500 
μm. 
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Figure 4.2: Lumenal SEM images of 20-30% w/w PCL scaffolds fabricated using SCPL. 
PCL dissolved in CHCl3 (A, B), EtOAc (C, D) and THF (E, F). Scale bar represents 1000 
μm. 
 
Regardless of solvent chosen and the PCL concentration, there appeared to be bubble-like 
films on the ablumenal surfaces. Since it was expected that the SCPL would produce 
scaffolds of varying porosity, the skin-like layer formation on the ablumenal surface was 
not anticipated. Interestingly for the lumenal porosity, the 20% concentration was better 
than the 30% concentration irrespective of the solvent used but these pores were isolated 
and not interconnected. The challenge is that both the ablumenal and lumenal surfaces did 
not produce consistently porous structures at all concentrations and instead 
morphologically resembled films. Despite using ammonium chloride porogens, the 
albumen and lumen morphologies observed in this study were consistent with a prior study 
that showed the solvent utilized to dissolve PCL dictated the surface morphology of casted 
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films due to the solubility of PCL in the various solvents with differences occurring at each 
interface, either glass or air.[153] In this cited study, film microporosity was observed at the 
polymer-glass interface when utilizing CHCl3 and THF but not EtOAc. However, in the 
current study, all solvents appeared to produce similar effect on scaffold morphology when 
in contact with the steel mandrel in the lumen or the glass tube in the ablumen. The 
variation between the lumenal and the ablumenal surfaces likely reflect the different 
surface properties between the two materials. Although surface contamination was a 
possibility, both the glass rod and steel mandrel were washed in the respective solvent for 
each specific run and left to air dry prior to use – making this unlikely to be a confounding 
influence. To evaluate if the surface chemistry of the mandrel had any effect, a Teflon™ 
rod was utilized as a replacement for the steel mandrel on the basis of its low surface energy 
which may alter interface phenomena.[154] However, similar morphological effects were 
observed with the replacement mandrel (data not shown). 
 
In addition to the lumen and albumen, the cross-section morphology was also investigated 
(Figure 4.3). With the exception of scaffolds fabricated using THF as a solvent (Fig. 4.1 F, 
H, I), all scaffolds were porous, interconnected, well-defined and open-faced. In the case 
of THF, however, the pores were not interconnected and the pore interconnecting windows 
were also sparse. A recent work by Choudhury et al.[155] suggested that the solvent may 
play a significant role in altering the porosity of PLA scaffolds fabricated using SCPL. The 
CHCl3 and EtOAc however appeared to produce cross-sectional areas with suitable 
porosity and comparable morphology. Given the evaporation rate differences between the 
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solvents used, the solvent-polymer interaction may be altered through thermodynamic 
means during evaporation and this may affect scaffold morphology when THF was used.  
 
Figure 4.3: SEM cross-sectional images of 20-30% w/w PCL tubular scaffolds fabricated 
using SCPL. PCL was dissolved in CHCl3 (A-C); EtOAc (D-F) and THF (G-I). Scale bar 
represents 500 μm. 
 
4.1.3 Micro-CT analysis of 3-D Scaffolds  
Since SEM is a qualitative technique, micro-computed tomography (micro-CT), which is 
a non-destructive and quantitative imaging technique[156], was used. Representative micro-
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CT images and the quantification of scaffold morphology and features are presented in 
Figure 4.4 and Table 4.2 respectively. 
 
Figure 4.4: Micro-CT images of PCL scaffolds fabricated by dissolving in either CHCl3 
or EtOAc at varying w/w concentrations. A-C. PCL dissolved in CHCl3. D-F. PCL 
dissolved in EtOAc. The images are specific volume elements representing the cross-
section within the scaffolds. The white within the image represents PCL and the grey 
regions represent the pores. 
 
Table 4.2: Micro-CT analysis of 3-D PCL scaffolds at varying w/w concentrations 
dissolved in either CHCl3 or EtOAc. Two different scaffolds were fabricated and three 
random measurements were taken for each scaffold (n = 6). 
 
Solvent PCL 
Concentration 
(w/w) 
Surface Area 
to Volume 
Ratio (mm-1) 
Strut 
Thickness 
(μm) 
Pore Diameter 
(μm) 
Overall 
Porosity (%) 
 
EtOAc 
20% 68.4±1.81 29.3±0.835 133±29.0 80.7±1.83 
25% 63.9±6.85 31.5±3.43 137±7.88 81.1±2.72 
30% 65.1±1.75 30.8±0.853 99.7±20.2 76.1±3.31 
 
CHCl3 
20% 53.6±0.114 37.4±0.0540 255±1.69 87.1±0.250 
25% 55.9±1.27 35.8±0.811 123±0.348 77.4±0.474 
30% 49.3±1.67 40.6±1.34 107±8.69 72.5±2.25 
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The effect of both polymer concentration and solvent used were determined by assessing 
the overall porosity, strut thickness, surface area to volume ratio, and pore size. The need 
to determine the scaffold parameters was based on the fact that the scaffold architecture is 
related to not only the mechanical properties of the scaffold but also to the manner in which 
cells would interact with the scaffold upon seeding.[156] All the scaffolds have sufficient 
porosity (72% – 87%) suitable for cell seeding and infiltration and were within the range 
of porosities that are often considered as ideal.[157] There is a clear trend that increasing 
PCL concentration led to lower scaffold porosity and strut thickness which were expected. 
The surface area to volume ratio of the scaffolds appeared to be dependent on the type of 
solvent used instead of the PCL concentration where by scaffolds fabricated using EtOAc 
had higher surface area to volume ratio than those fabricated using CHCl3. It is known that 
for a scaffold needs to be highly porous while possessing a high surface area to volume 
ratio to allow for suitable cell attachment and spreading.[158]  Surprisingly the pore 
diameters obtained from micro-CT measurements were much lower than the particle size 
of the porogens used (180 – 212 microns). This was not anticipated and the scaffold pore 
sizes may be underestimated by the micro-CT measurements since NH4Cl particles are 
insoluble in the organic solvents to explain size reduction during the scaffold fabrication 
process. Based on overall scaffold features shown in Table 4.2, scaffolds fabricated from 
30% PCL in EtOAc were chosen for subsequent cell culture studies.   
 
4.2 Assessing Cell Viability and Proliferation 
Cell viability was evaluated using two cell types: NIH-3T3 fibroblasts and hcSMCs. NIH-
3T3 fibroblasts were cultured on either 20%, 25%, or 30% PCL porous scaffolds for 4 or 
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7 days in 96-well plates. The cells were seeded at 9 x 105 cells/scaffold and cultured without 
additional biochemical factors. NIH-3T3 cells are known to proliferate faster than primary 
cells[159]; thus NIH-3T3 cells could be least impacted by a change in the environment in 
which they are seeded in and thus an MTT assay over 4 or 7 days would be suitable for an 
assessment of viability.  
 
As presented in Figure 4.5A, there was no significant difference in NIH-3T3 viability for 
4 days and 7 days culture on both 25% and 30% PCL concentrations. However, at a PCL 
concentration of 20%, there was a significant difference between day 4 and day 7 where 
cells cultured for 7 days had increased metabolic activity. Furthermore, cells cultured on 
30% PCL concentration for 7 days had significantly lower metabolic activity than those 
cultured at 20% for 7 days. The cell viability assay was repeated on hcSMCs by seeding 
4.5x105 cells/scaffold. As shown in Figure 4.5B, unlike the NIH-3T3 fibroblasts, the 
hcSMCs viability increased both with PCL concentration and with increased culture time.  
Unexpectedly, there appears to be a diverging trend on the metabolic activity the two cell 
types tested. While NIH-3T3 cells were metabolically more active at 20% PCL 
concentration, hcSMCs were more active at 30% PCL concentration. Although it remained 
to be tested, cell spreading and phenotype variation may be one factor.      
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Figure 4.5: MTT assays of NIH-3T3 fibroblasts or hcSMCs on 20%, 25%, or 30% w/w 
PCL scaffolds dissolved in EtOAc. A: Viability of NIH-3T3 fibroblasts assessed at day 4 
and 7. B: Viability of hcSMCs assessed at day 4 and 7. Significance: p<0.05 (*). 
 
Varying the scaffold polymer concentration was thought to have a role in influencing the 
ability of the cells to adhere to the scaffold and proliferate. In hydrogel systems, increasing 
the polymer concentrations within scaffolds can significantly reduce cell viability.[160] 
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However, the likely reason to this in hydrogel systems are the higher cross-linking densities 
which limit the mass transfer characteristics.[161] In electrospinning systems, increasing the 
polymer concentration can result in a non-linear relationship between solution 
concentration and fiber diameter whereas increased fibers diameters result in lower 
viability.[162] However, there was no study found in the literature of cell viability in the 
SCPL process at various polymer concentrations which is surprising given that scaffold 
architecture is paramount to cellular behavior.[156] 
 
To evaluate if the increase in viability of the hcSMCs correlated with that of an increase in 
proliferation, DNA quantification was conducted. It is known that an MTT metabolic assay 
does not always parallel observations seen in the more quantitative DNA assay in 3-D 
cultures.[163] As the 30% PCL concentration showed significantly higher hcSMCs viability, 
it was chosen to for cell proliferation study. The proliferation of the hcSMCs seeded on the 
30% PCL concentration at days 4 and 7 is shown in Figure 4.6. By day 7, the cell number 
was significantly higher than day 4, confirming the trend suggested by the MTT data and 
ability of the 30% PCL scaffolds to support and promote proliferation over time. 
Considering both the MTT and DNA quantification data, the 30% PCL scaffolds prepared 
in EtOAc were deemed to support cell viability and growth over time most optimally and 
were utilized in subsequent cell culture experiments. 
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Figure 4.6: DNA quantification of hcSMCs seeded onto 30% w/w PCL scaffolds at days 
4 and 7. Significance: p<0.05 (*), p<0.01 (**), p<0.001 (***). 
 
4.3 The Effect of atRA on Cultured Smooth Muscle Cells  
4.3.1 Cell Morphological Response to atRA Treatment 
Before studying the effect was atRA on elastin expression on PCL scaffolds, it was thought 
that any potential toxic effects that atRA may have on the hcSMCs should be explored. 
While most studies occurred in 2-D cultures, one prior study investigated atRA treatment 
on vSMCs in 3-D culture using aortic SMCs.[138] In a direct comparison with non-coronary 
medial SMCs, it was found that hcSMCs may differ in gene expression and response to 
biochemical factor treatment in culture.[164] Additionally, it is known that the response to 
factors can vary between 2-D and 3-D microenvironments. Lin et al. demonstrated that 
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hcSMCs can vary in their response to TGF-β1, with a more pronounced elastogenic 
response in 3-D than 2-D culture.[111] Since there are no prior studies about the effect of 
atRA on the viability of hcSMCs seeded onto 3-D porous scaffolds, it seemed reasonable 
to assess its suitability. In order to have a clean system that does not confound results, a 
non-degradable polyurethane scaffold was fabricated in the same way as the PCL scaffolds. 
There are no degradation products in this polyurethane (at least in the short term); thus cell 
phenotype will not be affected and does not confound results as per previous publications 
from Mequanint's lab [111, 139, 149, 158, 165, 166]. There is little difference between the model 
polyurethane scaffold and PCL in terms of hydrophobicity indicating that cells would not 
significantly favor one polymer over the other for cell adhesion. Additionally, both were 
pre-conditioned in buffer which  has been shown to increase the hydrophilicity of the 
polymers and improve cell viability.[167] 
 
100 μM of atRA concentration was added to hcSMCs seeded on porous polyurethane 
scaffolds and confocal images were taken after culturing for 4 and 7 days. The confocal 
images presented in Figure 4.7 revealed that hcSMCs formed a dense layer surrounding 
the scaffold struts with no indication of cytoskeletal or DNA fragmentation. At day 7, cells 
were observed bridging the scaffold pores suggesting active migration.   
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Figure 4.7: Confocal images of hcSMCs seeded onto porous 3-D polyurethane scaffolds 
and exposed to 100 μM of atRA. Confocal images were taken after 4 and 7 days of culture. 
Scale bar represents 200 μm. Staining: F-actin (green) and DAPI (red). 
 
While 100 μM of atRA appeared to support growth and suitable spreading by day 7, the 
effect of fibronectin coating and cultures longer than 7 days were studied. The rationale for 
fibronectin coating was that, it is a frequently used ECM component to enhance cell 
attachment and spreading on scaffolds through its RGD motif that can facilitate integrin 
binding.[168, 169] There are many studies that utilize fibronectin to increase cellular 
attachments to scaffolds to accelerate favorable cell-scaffold interactions.[169-171] The 
rationale for longer time culture (14 days) was that cells may respond differently to 
sustained atRA treatment compared to shorter times. Figure 4.8 displays confocal images 
of hcSMCs at day 14 on the porous 3-D model polyurethane scaffold. While cells were 
observed spreading on the fibronectin-coated scaffolds with abundant F-actin, the 
treatment of cells with 150 μM atRA resulted in diminished F-actin suggesting cell death. 
It is suggested that atRA can increase the expression of β1-integrin which can interact 
strongly with fibronectin.[172]  
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Figure 4.8: Confocal images of hcSMCs seeded on a porous 3-D polyurethane scaffold 
with or without fibronectin pre-treatment and 150 μM atRA. Cells were cultured for 14 
days before fixation and confocal imaging. Scale bar represents 200 μm. Staining: F-actin 
(green) and DAPI (red). 
 
It is worthy to note that cells had similar morphology and density regardless of fibronectin 
treatment. In view of this and since fibronectin may play a role in influencing elastin 
synthesis by shifting vSMCs into a more synthetic phenotype [173], its presence may further 
confound the effect of atRA and therefore, was precluded from further studies. Grenier et 
al.[166] found that when hcSMCs were cultured on fibronectin coated porous 3-D scaffolds, 
the expression of vSMC contractile phenotypic markers was reduced. As elastogenesis is 
known to likely be enhanced in the synthetic state, fibronectin may influence the way in 
which cells respond to biochemical factor stimulation in the context of elastin expression. 
While the design of the current study was focused on assessing differences between 2-D 
and 3-D microenvironments and how cell responses will vary to biochemical factor 
exposure, future studies may investigate the impact that various coatings would have on 
elastogenesis. While Grenier et al.[166] focused on fibronectin and Matrigel coatings, that 
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study did not assess elastin at the transcriptional or translational level. The impact of 
understanding how coating with ECM proteins could increase elastogenesis may be 
invaluable for future experimental designs attempting to augment elastogenesis for VTE. 
 
4.3.2 The effect of atRA Concentration on Elastin Gene Expression  
The concentration of atRA may affect tropoelastin transcription in a dose-dependent 
manner. To test this, hcSMCs were seeded in 2-D culture plates and were treated with 
different concentrations of atRA (0.1 to 10 M) over 4 days culture. While it can be 
expected that the elastogenic effect of atRA may vary temporally, the response to varying 
concentrations should be consistent with time. As shown in Figure 4.9, the concentration 
that promoted the highest fold increase in tropoelastin transcription occurred when using 
10 μM atRA; producing a 2-fold increase in gene expression. While 0.1 and 1 μM atRA 
also increased tropoelastin mRNA levels compared to the untreated control, the fold 
increase was not significant. Based on the observations of Figures 4.7 and 4.8, it was 
tempting to increase the atRA concentration to boost elastin in the gene expression study. 
Although 100 μM and 150 μM were investigated for the confocal studies, these 
concentrations are not physiological and may have other negative effects beyond boosting 
elastin expression. Therefore, it was decided to limit the gene/protein expression studies to 
reported physiological atRA concentration ranges.[113]  Not withstanding this, higher 
concentration of atRA would be tolerated in vivo, as documented for acute promyelocytic 
leukemia chemotherapy.[174] In vitro studies suggested that utilizing higher atRA 
concentrations would result in a decrease in vSMC proliferative ability which emphasized 
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the need to select a lower concentration while still facilitating the highest increase in 
tropoelastin transcriptional activity.[123, 175] 
 
 
Figure 4.9: The effect of atRA concentration on tropoelastin gene expression in hcSMCs 
cultured on 2D plates for 4 days. 10 μM atRA produced the highest tropoelastin fold 
increase and was utilized for subsequent experiments. Significance: p<0.05 (*) was 
observed for 10 μM of atRA compared to the untreated control (C) and 0.1 and 1 μM of 
atRA. 
 
4.4 The Effect of AA and atRA Combination on Tropoelastin Synthesis 
As the concentration of atRA in gene expression experiments was maximum at 10 μM, the 
effect on tropoelastin protein expression due to a combined treatment of AA and atRA was 
investigated. Although AA has been reported to decrease elastogenesis in 2-D cultures[137], 
the rationale behind the biochemical factor’s use was to increase collagen expression[136, 
137] since both elastin and collagen are essential ECM components of a vascular tissue. 
Thus, as atRA has been reported to increase elastin [133], it was necessary to investigate the 
interaction between the two biochemical factors. However, there have been limited studies 
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investigating the effect of the combination of AA and atRA on elastogenesis in hcSMCs 
with the work by Ogle et al. being the lone consideration.[138] Ideally, the ability to increase 
elastin with combined biochemical factor treatment would enhance vascular tissue 
fabrication. Thus, the premise of the investigation was that while atRA and AA would show 
an increase and decrease in elastin expression respectively, it was unknown to what effect 
the combination would have. To test this, a time-course experiment (24 hours – 96 hours) 
was conducted in 2-D culture plates after the cells had reached confluence. The reason for 
reaching cell confluency before biochemical factors treatment  was to limit the effect of 
phenotypic modulation in culture.[24]  
 
As shown in Figure 4.10, the increased tropoelastin expression when supplemented with 
atRA was significantly higher at all time points relative to AA alone. Conversely, AA 
decreased elastin expression compared with atRA alone at all time-points. The combined 
AA and atRA treatment significantly decreased tropoelastin synthesis at all time points. 
This suggested that the effect of the combination was influenced to a greater extent by AA 
as no significant differences were observed between AA and the combination at the tested 
time-points while significance occurred between atRA alone and the combined treatment. 
It was suspected that AA may be exerting its effects at an earlier stage of tropoelastin 
synthesis whereas atRA functions at a later stage. For instance, studies suggested that atRA 
may influence tropoelastin mRNA stability while it is known that AA may exert its effect 
earlier, directly at the transcriptional level.[137] 
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Figure 4.10: Time-course evaluation tropoelastin synthesis (as determined by Western 
blot) isolated from whole-cell lysates of hcSMCs in response to various biochemical factor 
treatments. Data are normalized to GAPDH and a control without biochemical factor 
treatment. Significance: p<0.05 (*) was observed as indicated in the graph.  
 
It seems likely that less tropoelastin mRNA may be produced for the atRA to stabilize 
which may account for the similar protein expression patterns generally observed between 
AA and the combination treatment. To evaluate this possibility, tropoelastin transcription 
experiments at 48, 72, and 96 hours were conducted. As shown in Figure 4.11 the 
tropoelastin mRNA expression levels were not significantly different compared with the 
control at 72 and 96 hours, which correlated with the protein expression levels seen in 
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Figure 4.10. However, there was a significant increase (5.5-fold increase) at the 48 hour 
time point. Taken together, this may suggest that while temporal variation exists in terms 
of transcriptional activity, the effect of the decrease in tropoelastin protein expression with 
combined atRA and AA treatment is very likely attributed to transcriptional repression.  
 
Figure 4.11: qPCR assessing tropoelastin transcription in hcSMCs at 48, 72, and 96 hours 
comparing a combination of AA and atRA to a non-treated control, both normalized to 
GAPDH. Significance: p<0.05 (*) was observed for the combination treatment relative to 
the untreated control at the 48-hour time point. NS: Not significant. 
 
4.5 Comparative Study of Elastin Synthesis in 2D Plates and 3D PCL Scaffolds  
4.5.1 Spatial Effects on Elastin Synthesis  
The effect of the culture microenvironment on elastin synthesis was evalauted at days 4 
and 7 by seeding the hcSMCs onto 2-D culture plates and 3-D porous PCL scaffolds. 
Elastin expression at days 4 and 7 in 2-D and 3-D cultures is shown in Figure 4.12. 
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Figure 4.12: Western blotting of whole-cell lysates of hcSMCs assessing for tropoelastin 
expression in response to biochemical factor treatment in 2D culture plates (A) and 3D 
PCL scaffolds (B). Data was normalized to GAPDH and a non-treated control. 
Significance: p<0.05 (*).  
 
Two observations can be made from Figure 4.12: (i) The protein expression levels had 
similar patterns between 2-D and 3-D, and (ii) similar to short culture times (Figure 4.10), 
the combined treatment reduced elastin expression in 3-D. This suggests that although the 
cells are seeded in different environments, the effects of the biochemical factor stimulation 
on elastin expression are not spatially dependent. Notwithstanding this, the amount of 
elastin produced was more pronounced in 3-D. This is consistent with work by Lin et al.[111] 
who suggested that the 3-D environment alone is sufficient to increase elastin expression 
relative to 2-D cultures. However, the effect of AA in 3-D cultures appears to be low 
compared to 2-D cultures at day 4. By day 7, the lowering of elastin protein expression in 
response to AA treatment or a combination with atRA was alleviated and rose to levels 
similar to those seen in the non-treated controls. While the experimental time-point ended 
at day 7, it would be interesting to study if the reduction seen in 3-D compared to atRA 
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alone would be overcome at longer time-points. Previous work by Ogle et al. [138] 
examining the combination treatment in 3-D did not investigate the impact of atRA or AA 
alone on elastin protein expression in 3-D and thus it is difficult to make direct comparison. 
 
4.5.2 Combinational Approach to Rescue Elastin Expression in 3-D Culture 
The decrease in elastin protein expression with the combination treatment compared to that 
of atRA alone was unfortunate as both factors are required for either increasing collagen 
or elastin and are thus necessary for engineering viable vascular tissues. As the experiments 
in both 2-D and 3-D suggested that AA was lowering elastin synthesis, a new approach 
was devised. To maintain the elastogenic effect of atRA while preserving the ability of AA 
to increase collagen expression, a sequential treatment was attempted. AA was initially 
supplemented to increase collagen expression prior to stopping AA stimulation and 
providing atRA treatment. This was implemented to test if elastin expression can be 
rescued after the expected decrease in response to AA treatment. As Figure 4.13 
demonstrates, the effect of AA seemed to have a significant impact on elastin expression 
even when the AA was removed from the culture environment. Removal of AA for 1 and 
3 days did not result in a significant difference compared to the control over the 7 days 
culture. This suggests that both 1 day and 3 days exposure was not sufficient produce 
elastin at the level observed when atRA was added alone over 4 day assay (compare Fig 
4.13 with Fig 4.10 and 4.12). However, there was a significant difference between AA 
treatment alone over the 7 days and 3 days of rescue with the atRA. This suggested that the 
repression on elastin synthesis induced by AA can be overcome by subsequent addition 
atRA, though it may take longer than 1 day to observe an effect. 
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Figure 4.13: Elastin expression assessed by Western blotting of whole-cell lysates of 
hcSMCs after sequential non-overlapping factor exposure for different times. The 
schematic of the experimental design is shown in A where cells were cultured either 
without treatment (control), 6 days of AA treatment, 5 days AA followed by 1 day atRA 
treatment or 3 days AA followed by 3 days atRA treatment.  Cells were harvested on the 
7th day for protein extraction and Western blotting. Significance: p<0.05 (*) was observed 
for 3 days of atRA rescue compared to AA alone. 
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It is possible that the collagen expression stimulated by AA may have suppressed elastin 
expression and this is plausible. Although collagen gels are commonly utilized in VTE they 
have been shown to suppress elastogenic effects in vitro.[11] Another possibility for this 
temporal suppression could be that some AA is adsorbed onto the surfaces of the PCL 
scaffold and acted on the smooth muscle cells for longer times than anticipated. However, 
given the rapid oxidation of AA in tissue culture environments, this is unlikely.[176] This 
suggests that AA may have delayed inhibitory effects on elastogenesis. It would be 
interesting to examine the effect of atRA treatment first followed by AA on elastin and 
collagen synthesis or using a longer sequential non-overlapping factor exposure to observe 
if the AA mediated decrease can be mitigated with time. 
 
4.5.3 The Effect of Biochemical Factors on α-SMA Expression 
As there is a known correlation with ECM synthesis and vSMC phenotype, the effect of 
biochemical factor stimulation on the phenotype was investigated in both 2-D and 3-D 
cultures. However, when assessing vSMC phenotypic plasticity, it is known that there can 
be significant heterogeneity within a culture, thus making the phenotype difficult to 
assess.[177] In spite of this, atRA has been shown to induce vSMCs to progress to a more 
contractile phenotype in 2-D.[118, 119] There is no data on the effect that AA may have on 
vSMC phenotype in 3-D cultures. As AA reduced elastin protein expression at both day 4 
and day 7, the role of AA in cell phenotype was investigated (Figure 4.14). While there are 
numerous contractile protein markers, α-SMA is associated with an earlier/mid stage 
differentiation marker was chosen in comparison to the more mature markers such as 
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smooth muscle myosin-heavy chain which occur at later time-points.[105] It was thought 
that α-SMA would indicate the onset of transition to the contractile phenotype. 
 
Figure 4.14: Western blotting of whole-cell lysates of hcSMCs assessing for α-SMA 
normalized to GAPDH at day 4 and day 7 cultures for 2D cultures (A, B) and 3D cultures 
(C, D). Significance: p<0.05 (*).  
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In 2-D, α-SMA expression levels were similar across treatment groups at both day 4 and 
day 7; however, α-SMA expression was significantly higher on the 3-D combination 
treated cultures at day 7 than all other treatments. This suggests that elastin expression in 
2-D may be independent from the adoption of a contractile phenotype when treated with 
AA alone or in combination with atRA. Moreover, the lack of significance for all 
biochemical factor treatments relative to the controls at both day 4 and day 7 indicates that 
in 2-D these biochemical factors possess little phenotypic influence compared to the 
seeding environment alone. Generally stiffer substrates induce a more synthetic 
phenotype.[106] It appears that AA or the combination treatment have no effect on α-SMA 
expression in both 2-D and 3-D cultures to induce the contractile phenotype. As atRA was 
expected to promote the contractile state, in 2-D, the AA mediated influence on low elastin 
expression appears to be potentially dependent on phenotype. The current data is consistent 
with a study conducted by Ryan et al.[178] who suggested that in collagen gels, insoluble 
elastin can induce a contractile phenotype characterized by an increase in α-SMA.  
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Chapter 5 – Conclusions and Future 
Directions 
 
5.1 Conclusions 
The present study assessed the SCPL process for PCL scaffold fabrication. The scaffolds 
were then utilized for culturing smooth muscle cells with biochemical factors to enhance 
elastin synthesis. The initial scaffold fabrication considered PCL dissolved in varying 
concentrations and solvents. It was found that a hold time of 2 hours in the glass rod 
produced the best scaffolds as shorter times led to disintegration and longer times resulted 
in an inability to remove the scaffold from the glass tube casing irrespective of solvent 
chosen and concentration of PCL. However, the type of the solvent was found to influence 
the morphology of the scaffolds. SEM studies showed that THF produced scaffolds that 
have poorly-interconnected and closed pores. In tubular scaffolds, all solvents produced 
bubble-like films on the ablumen and isolated pores in the lumen regardless of the PCL 
concentration. Micro-CT was used to identify EtOAc as the best solvent to fabricate the 
PCL scaffolds based on overall porosity, strut thickness, and surface area to volume ratio. 
Given the higher ratios obtained with EtOAc as the solvent, it was used in the scaffold 
fabrication for subsequent cell culture studies. MTT assay using NIH-3T3 fibroblasts and 
hcSMCs on PCL scaffolds fabricated from 20, 25, 30% concentration showed an opposite 
trend as a function of PCL used to fabricate the scaffolds likely due to differences in 
metabolic activity and proliferation rate between the two cell lines. While 30% resulted in 
significantly less viability than seen with 20% for the NIH-3T3 fibroblasts, 30% promoted 
the highest viability with hcSMCs which was confirmed with a more quantitative DNA 
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assay. Given the higher viability and proliferation observed with the hcSMCs and as the 
30% PCL concentration was more mechanically stable, it was chosen for elastogenic 
studies. qPCR confirmed that 10 μM atRA promoted the highest tropoelastin 
transcriptional activity and confocal imaging on model polyurethane scaffolds indicated 
that higher concentrations at day 4 and 7 produced no cytotoxic effects. To evaluate the 
effect of AA and atRA, Western blotting of whole-cell lysates for tropoelastin was 
conducted. Significant increases in relative expression when treated with atRA alone 
occurred at 48 and 96 hours indicating that temporal variation exists in the elastogenic 
effect of atRA. However, the combination of AA and atRA expression more closely 
mirrored that of AA alone which indicated that AA may have a greater effect than atRA in 
2-D cultures. Similar trends were observed when comparing tropoelastin expression in 2-
D culture plates and 3-D PCL scaffolds, with atRA treatment alone significantly increasing 
expression compared to AA alone or the combination at both day 4 and day 7 in 3-D and 
day 7 in 2-D. Interestingly, when assessing whether this trend correlated with the 
phenotype of the hcSMCs in both 2-D and 3-D it was found that α-SMA remained constant 
in 2-D yet was increased over time with AA alone and the combination treatment. Given 
the decrease in elastin when combination treatment was used, a sequential treatment was 
shown to be effective to enhance elastin synthesis.  Overall, the study in this thesis provided 
insights into early responses of hcSMCs on SCPL PCL scaffolds and elastin synthesis in 
response to atRA and AA. 
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5.2 Future Directions 
Moving forward, the following future studies are suggested: 
 Conduct long-term cultures using the sequential addition of biochemical factors. 
 Combine biochemical factors with biomechanical forces to study the possible 
synergy between them 
 Understand molecular mechanisms of elastin synthesis in response to atRA in 3-D 
cultures. 
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